<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02379923</url>
  </required_header>
  <id_info>
    <org_study_id>AIUCT-001</org_study_id>
    <nct_id>NCT02379923</nct_id>
  </id_info>
  <brief_title>The Asahi Intecc PTCA Chronic Total Occlusion Study</brief_title>
  <acronym>CTO-PCI</acronym>
  <official_title>The Asahi Intecc PTCA Chronic Total Occlusion Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asahi Intecc USA Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asahi Intecc USA Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to evaluate confirmation of placement of any guidewire
      beyond the chronic total occlusion (CTO) in the true vessel lumen in patients in which at
      least one Asahi series of guidewires and/or Corsair microcatheter were used.

      Procedure success will be defined as angiographic visualization of any guidewire in a
      position either distal or proximal to the occlusion depending on the route of access and the
      absence of in-hospital major adverse cardiac events (MACE).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, multi-center, single-arm, intent-to-treat (ITT) study is designed to assess
      the safety and effectiveness of the investigational products for the treatment of CTOs in a
      native coronary artery.

      The primary objective of this trial is to evaluate confirmation of placement of any guidewire
      beyond the CTO in the true vessel lumen in patients in which at least one Asahi series of
      guidewires and/or Corsair microcatheter were used.

      The population for this study is subjects with signs and/or symptoms considered typical of
      ischemic heart disease attributed to a CTO in a native coronary artery, who are suitable for
      a percutaneous revascularization.

      Procedure success will be defined as angiographic visualization of any guidewire in a
      position either distal or proximal to the occlusion depending on the route of access and the
      absence of in-hospital major adverse cardiac events (MACE). All subjects are followed through
      hospital discharge.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedure Success</measure>
    <time_frame>Through hospital discharge, typically 24 hours post procedure</time_frame>
    <description>Angiographic visualization of any guidewire in a position either distal or proximal to the occlusion depending on the route of access and the absence of in-hospital MACE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of Successful Recanalization</measure>
    <time_frame>During Procedure</time_frame>
    <description>Angiographic confirmation of crossing the chronic total occlusion and restoring blood flow to the affected area.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of In-hospital MACE</measure>
    <time_frame>Up to hospital discharge</time_frame>
    <description>Any serious adverse experience that includes cardiac death; target lesion revascularization; or post-procedural MI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Perforation</measure>
    <time_frame>During Procedure</time_frame>
    <description>Frequency of perforation during the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Dissection</measure>
    <time_frame>During procedure</time_frame>
    <description>Frequency of dissection reported during the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Procedural Time</measure>
    <time_frame>During Procedure</time_frame>
    <description>The length of the procedure (The first successful insertion of the guide catheter at an arteriotomy site is considered the start of the procedure. A procedure is considered complete once the guide catheter is removed from the arteriotomy site.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Contrast Volume</measure>
    <time_frame>During Procedure</time_frame>
    <description>Volume of contrast administered during procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Absorbed Radiation Dose in mGy</measure>
    <time_frame>During Procedure</time_frame>
    <description>Absorbed radiation dose in mGy during procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success (Evaluated According to Crossing Technique)</measure>
    <time_frame>Through hospital discharge</time_frame>
    <description>The percentage of subjects with procedure success according to crossing technique</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">163</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Artery Chronic Total Occlusion</condition>
  <arm_group>
    <arm_group_label>Crossing of Coronary Artery CTO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a single arm intent to treat study. A subject is considered enrolled when the subject has given informed consent and meets all inclusion and exclusion criteria, including angiographic inclusion and exclusion criteria, which includes an attempt to cross the target lesion with an investigational device (ASAHI PTCA Guidewire or ASAHI Corsair Microcatheter). Clinical evaluation up to hospital discharge is conducted on all enrolled subjects. The purpose of the clinical follow-up is to determine if the subject has experienced or is experiencing any adverse events</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Crossing of Coronary Artery CTO</intervention_name>
    <description>Standard angiographic procedures will be followed for this study. The primary objective of this trial is to evaluate confirmation of placement of any guidewire beyond the chronic total occlusion (CTO) in the true vessel lumen in patients in which at least one Asahi series of guidewires and/or Corsair microcatheter were used.
Procedure success will be defined as angiographic visualization of any guidewire in a position either distal or proximal to the occlusion depending on the route of access and the absence of in-hospital MACE.
Other Name: ASAHI Corsair Microcatheter, ASAHI PTCA Guide Wires</description>
    <arm_group_label>Crossing of Coronary Artery CTO</arm_group_label>
    <other_name>Corsair, Gaia, Asahi Guide Wires</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  General Inclusion Criteria:

               1. Subject is â‰¥ 18 years of age at the time of consent

               2. Subject is experiencing clinical symptoms considered suggestive of ischemic heart
                  disease (e.g., chest pain or discomfort, heart failure, etc.) or has evidence of
                  myocardial ischemia (e.g., abnormal functional study) attributed to the CTO
                  target vessel and is scheduled for clinically indicated percutaneous
                  revascularization

               3. Subject is eligible and consents to undergo PCI procedure

               4. Subject is an acceptable candidate for percutaneous transluminal coronary
                  angioplasty (PTCA), stenting, and emergency coronary artery bypass grafting
                  (CABG)

               5. Subject is willing and able to sign an Informed Consent Form approved by a local
                  Institutional Review Board

               6. Female subjects of child-bearing potential must have a negative qualitative or
                  quantitative pregnancy test within 7 days before the study procedure

                  Angiographic Inclusion Criteria:

               7. A minimum of one de novo lesion with at least one target segment in a native
                  coronary vessel meeting definition of chronic total occlusion. Non-study lesions
                  will be treated first. A &quot;chronic total occlusion&quot; is any non-acute total
                  coronary occlusion fulfilling the angiographic characteristics consistent with
                  high-grade native coronary stenosis (TIMI 0) and estimated in duration at least 3
                  months by clinical history and/or comparison with antecedent angiogram or
                  electrocardiogram. An attempt to cross the target lesion with at least one Asahi
                  guidewire or a Corsair microcatheter must be made.

        Exclusion Criteria:

          -  General Exclusion Criteria:

               1. Subjects with any history of allergy to iodinated contrast that cannot be
                  effectively managed medically

               2. Evidence of acute Myocardial Infarction (MI) within 72 hours of the intended
                  treatment defined as cardiac enzymes greater than Upper Limit of Normal (ULN).

               3. Previous coronary interventional procedure of any kind within the 30 days prior
                  to the procedure

               4. Any contraindication to cardiac catheterization or to any of the standard
                  concomitant therapies used during routine cardiac catheterization and PCI (e.g.,
                  aspirin, clopidogrel, unfractionated heparin, etc.)

               5. Target lesion requires treatment with a device after successful crossing other
                  than PTCA prior to stent placement

               6. Subjects with known history of clinically significant abnormal laboratory
                  findings including:

                    -  Neutropenia (&lt;1000 neutrophils/mm3) within the previous 2 weeks

                    -  Thrombocytopenia (&lt;100,000 platelets/mm3)

                    -  AST, ALT, alkaline phosphatase, or bilirubin &gt; 1.5 Ã— ULN

                    -  Serum creatinine &gt; 2.0 mg/dL

               7. Subjects with evidence of ongoing or active clinical instability including the
                  following:

                    -  Sustained systolic blood pressure &lt; 100 mmHg or cardiogenic shock

                    -  Acute pulmonary edema or severe congestive heart failure

                    -  Suspected acute myocarditis, pericarditis, endocarditis, or cardiac
                       tamponade

                    -  Suspected dissecting aortic aneurysm

                    -  Hemodynamically significant valvular heart disease, hypertrophic
                       cardiomyopathy, restrictive cardiomyopathy, or congenital heart disease

               8. History of stroke or transient ischemic attack within the prior 6 months

               9. Active peptic ulcer or upper gastrointestinal (GI) bleeding within the prior 6
                  months

              10. History of bleeding diathesis or coagulopathy or refusal of blood transfusions

              11. Subjects with any other pathology such as cancer, mental illness, etc., which in
                  the opinion of the Investigator, might put the patient at risk, preclude
                  follow-up, or in any way confound the results of the study

              12. Known previous medical condition yielding expected survival less than 1 year

              13. Subjects who are unable or unwilling to comply with the protocol or not expected
                  to complete the study period, including its follow-up requirements

              14. Currently participating in an investigational drug or another device study that
                  has not completed the primary endpoint or that clinically interferes with the
                  current study endpoints;

                  Angiographic Exclusion Criteria:

              15. Occlusion involves segment within previous stent

              16. Extensive lesion-related thrombus (TIMI thrombus grade 3 or 4)

              17. Previous stenting (drug-eluting or bare metal) in the target vessel unless the
                  following conditions are met:

                    -  It has been at least 9 months since the previous stenting

                    -  That target lesion is at least 15 mm away from the previously placed stent

                    -  The previously stented segment (stent plus 5 mm on either side) has no more
                       than 40% diameter stenosis, based on visual estimate

              18. The target vessel has other lesions proximal to the total occlusion identified
                  with greater than 75% diameter stenosis based on visual estimate. However,
                  planned stenting of the lesion in target vessel which is proximal to the target
                  lesion and can be covered by a single stent (i.e., tandem lesions) are
                  acceptable.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Kandzari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Piedmont Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aaron Grantham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MidAmerica Heart Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner - University Medical Center Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of the Rockies</name>
      <address>
        <city>Loveland</city>
        <state>Colorado</state>
        <zip>80538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Healthcare</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Health and Hospitals Corp.</name>
      <address>
        <city>Oakbrook Terrace</city>
        <state>Illinois</state>
        <zip>60181</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>00029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center/New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PeaceHealth Sacred Heart Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Oregon</state>
        <zip>97477</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York Hospital</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas VA Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Park CS, Kim HY, Park HJ, Ihm SH, Kim DB, Lee JM, Kim PJ, Park CS, Moon KW, Yoo KD, Jeon DS, Chung WS, Seung KB, Kim JH. Clinical, electrocardiographic, and procedural characteristics of patients with coronary chronic total occlusions. Korean Circ J. 2009 Mar;39(3):111-5. doi: 10.4070/kcj.2009.39.3.111. Epub 2009 Mar 25.</citation>
    <PMID>19949597</PMID>
  </reference>
  <reference>
    <citation>Oesterle SN, Bittl JA, Leon MB, Hamburger J, Tcheng JE, Litvack F, Margolis J, Gilmore P, Madsen R, Holmes D, Moses J, Cohen H, King S 3rd, Brinker J, Hale T, Geraci DJ, Kerker WJ, Popma J. Laser wire for crossing chronic total occlusions: &quot;learning phase&quot; results from the U.S. TOTAL trial. Total Occlusion Trial With Angioplasty by Using a Laser Wire. Cathet Cardiovasc Diagn. 1998 Jun;44(2):235-43.</citation>
    <PMID>9637452</PMID>
  </reference>
  <results_reference>
    <citation>Kahn JK. Angiographic suitability for catheter revascularization of total coronary occlusions in patients from a community hospital setting. Am Heart J. 1993 Sep;126(3 Pt 1):561-4.</citation>
    <PMID>8362709</PMID>
  </results_reference>
  <results_reference>
    <citation>Christofferson RD, Lehmann KG, Martin GV, Every N, Caldwell JH, Kapadia SR. Effect of chronic total coronary occlusion on treatment strategy. Am J Cardiol. 2005 May 1;95(9):1088-91.</citation>
    <PMID>15842978</PMID>
  </results_reference>
  <results_reference>
    <citation>Sirnes PA, Golf S, Myreng Y, MÃ¸lstad P, Emanuelsson H, Albertsson P, Brekke M, Mangschau A, Endresen K, Kjekshus J. Stenting in Chronic Coronary Occlusion (SICCO): a randomized, controlled trial of adding stent implantation after successful angioplasty. J Am Coll Cardiol. 1996 Nov 15;28(6):1444-51.</citation>
    <PMID>8917256</PMID>
  </results_reference>
  <results_reference>
    <citation>Moussa I, Di Mario C, Moses J, Reimers B, Di Francesco L, Blengino S, Colombo A. Comparison of angiographic and clinical outcomes of coronary stenting of chronic total occlusions versus subtotal occlusions. Am J Cardiol. 1998 Jan 1;81(1):1-6.</citation>
    <PMID>9462596</PMID>
  </results_reference>
  <results_reference>
    <citation>Sirnes PA, Golf S, Myreng Y, MÃ¸lstad P, Albertsson P, Mangschau A, Endresen K, Kjekshus J. Sustained benefit of stenting chronic coronary occlusion: long-term clinical follow-up of the Stenting in Chronic Coronary Occlusion (SICCO) study. J Am Coll Cardiol. 1998 Aug;32(2):305-10.</citation>
    <PMID>9708454</PMID>
  </results_reference>
  <results_reference>
    <citation>Surmely JF, Tsuchikane E, Katoh O, Nishida Y, Nakayama M, Nakamura S, Oida A, Hattori E, Suzuki T. New concept for CTO recanalization using controlled antegrade and retrograde subintimal tracking: the CART technique. J Invasive Cardiol. 2006 Jul;18(7):334-8.</citation>
    <PMID>16816442</PMID>
  </results_reference>
  <results_reference>
    <citation>Suero JA, Marso SP, Jones PG, Laster SB, Huber KC, Giorgi LV, Johnson WL, Rutherford BD. Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience. J Am Coll Cardiol. 2001 Aug;38(2):409-14.</citation>
    <PMID>11499731</PMID>
  </results_reference>
  <results_reference>
    <citation>Olivari Z, Rubartelli P, Piscione F, Ettori F, Fontanelli A, Salemme L, Giachero C, Di Mario C, Gabrielli G, Spedicato L, Bedogni F; TOAST-GISE Investigators. Immediate results and one-year clinical outcome after percutaneous coronary interventions in chronic total occlusions: data from a multicenter, prospective, observational study (TOAST-GISE). J Am Coll Cardiol. 2003 May 21;41(10):1672-8.</citation>
    <PMID>12767645</PMID>
  </results_reference>
  <results_reference>
    <citation>Prasad A, Rihal CS, Lennon RJ, Wiste HJ, Singh M, Holmes DR Jr. Trends in outcomes after percutaneous coronary intervention for chronic total occlusions: a 25-year experience from the Mayo Clinic. J Am Coll Cardiol. 2007 Apr 17;49(15):1611-1618. doi: 10.1016/j.jacc.2006.12.040. Epub 2007 Apr 2.</citation>
    <PMID>17433951</PMID>
  </results_reference>
  <results_reference>
    <citation>Valenti R, Migliorini A, Signorini U, Vergara R, Parodi G, Carrabba N, Cerisano G, Antoniucci D. Impact of complete revascularization with percutaneous coronary intervention on survival in patients with at least one chronic total occlusion. Eur Heart J. 2008 Oct;29(19):2336-42. doi: 10.1093/eurheartj/ehn357. Epub 2008 Aug 5.</citation>
    <PMID>18682446</PMID>
  </results_reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>February 23, 2015</study_first_submitted>
  <study_first_submitted_qc>March 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2015</study_first_posted>
  <results_first_submitted>June 19, 2018</results_first_submitted>
  <results_first_submitted_qc>June 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 18, 2018</results_first_posted>
  <last_update_submitted>June 19, 2018</last_update_submitted>
  <last_update_submitted_qc>June 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Crossing of Coronary Artery CTO</title>
          <description>This is a single arm intent to treat study. A subject is considered enrolled when the subject has given informed consent and meets all inclusion and exclusion criteria, including angiographic inclusion and exclusion criteria, which includes an attempt to cross the target lesion with an investigational device (ASAHI PTCA Guidewire or ASAHI Corsair Microcatheter). Clinical evaluation up to hospital discharge is conducted on all enrolled subjects. The purpose of the clinical follow-up is to determine if the subject has experienced or is experiencing any adverse events.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="158"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Crossing of Coronary Artery CTO</title>
          <description>This is a single arm intent to treat study. A subject is considered enrolled when the subject has given informed consent and meets all inclusion and exclusion criteria, including angiographic inclusion and exclusion criteria, which includes an attempt to cross the target lesion with an investigational device (ASAHI PTCA Guidewire or ASAHI Corsair Microcatheter). Clinical evaluation up to hospital discharge is conducted on all enrolled subjects. The purpose of the clinical follow-up is to determine if the subject has experienced or is experiencing any adverse events.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="163"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.5" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Procedure Success</title>
        <description>Angiographic visualization of any guidewire in a position either distal or proximal to the occlusion depending on the route of access and the absence of in-hospital MACE.</description>
        <time_frame>Through hospital discharge, typically 24 hours post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crossing of Coronary Artery CTO</title>
            <description>This is a single arm intent to treat study. A subject is considered enrolled when the subject has given informed consent and meets all inclusion and exclusion criteria, including angiographic inclusion and exclusion criteria, which includes an attempt to cross the target lesion with an investigational device (ASAHI PTCA Guidewire or ASAHI Corsair Microcatheter). Clinical evaluation up to hospital discharge is conducted on all enrolled subjects. The purpose of the clinical follow-up is to determine if the subject has experienced or is experiencing any adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Procedure Success</title>
          <description>Angiographic visualization of any guidewire in a position either distal or proximal to the occlusion depending on the route of access and the absence of in-hospital MACE.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Successful Recanalization</title>
        <description>Angiographic confirmation of crossing the chronic total occlusion and restoring blood flow to the affected area.</description>
        <time_frame>During Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crossing of Coronary Artery CTO</title>
            <description>This is a single arm intent to treat study. A subject is considered enrolled when the subject has given informed consent and meets all inclusion and exclusion criteria, including angiographic inclusion and exclusion criteria, which includes an attempt to cross the target lesion with an investigational device (ASAHI PTCA Guidewire or ASAHI Corsair Microcatheter). Clinical evaluation up to hospital discharge is conducted on all enrolled subjects. The purpose of the clinical follow-up is to determine if the subject has experienced or is experiencing any adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Successful Recanalization</title>
          <description>Angiographic confirmation of crossing the chronic total occlusion and restoring blood flow to the affected area.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of In-hospital MACE</title>
        <description>Any serious adverse experience that includes cardiac death; target lesion revascularization; or post-procedural MI.</description>
        <time_frame>Up to hospital discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crossing of Coronary Artery CTO</title>
            <description>This is a single arm intent to treat study. A subject is considered enrolled when the subject has given informed consent and meets all inclusion and exclusion criteria, including angiographic inclusion and exclusion criteria, which includes an attempt to cross the target lesion with an investigational device (ASAHI PTCA Guidewire or ASAHI Corsair Microcatheter). Clinical evaluation up to hospital discharge is conducted on all enrolled subjects. The purpose of the clinical follow-up is to determine if the subject has experienced or is experiencing any adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of In-hospital MACE</title>
          <description>Any serious adverse experience that includes cardiac death; target lesion revascularization; or post-procedural MI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Perforation</title>
        <description>Frequency of perforation during the procedure.</description>
        <time_frame>During Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crossing of Coronary Artery CTO</title>
            <description>This is a single arm intent to treat study. A subject is considered enrolled when the subject has given informed consent and meets all inclusion and exclusion criteria, including angiographic inclusion and exclusion criteria, which includes an attempt to cross the target lesion with an investigational device (ASAHI PTCA Guidewire or ASAHI Corsair Microcatheter). Clinical evaluation up to hospital discharge is conducted on all enrolled subjects. The purpose of the clinical follow-up is to determine if the subject has experienced or is experiencing any adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Perforation</title>
          <description>Frequency of perforation during the procedure.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Dissection</title>
        <description>Frequency of dissection reported during the procedure</description>
        <time_frame>During procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crossing of Coronary Artery CTO</title>
            <description>This is a single arm intent to treat study. A subject is considered enrolled when the subject has given informed consent and meets all inclusion and exclusion criteria, including angiographic inclusion and exclusion criteria, which includes an attempt to cross the target lesion with an investigational device (ASAHI PTCA Guidewire or ASAHI Corsair Microcatheter). Clinical evaluation up to hospital discharge is conducted on all enrolled subjects. The purpose of the clinical follow-up is to determine if the subject has experienced or is experiencing any adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Dissection</title>
          <description>Frequency of dissection reported during the procedure</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Procedural Time</title>
        <description>The length of the procedure (The first successful insertion of the guide catheter at an arteriotomy site is considered the start of the procedure. A procedure is considered complete once the guide catheter is removed from the arteriotomy site.)</description>
        <time_frame>During Procedure</time_frame>
        <population>Data collected for 162 of 163 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Crossing of Coronary Artery CTO</title>
            <description>This is a single arm intent to treat study. A subject is considered enrolled when the subject has given informed consent and meets all inclusion and exclusion criteria, including angiographic inclusion and exclusion criteria, which includes an attempt to cross the target lesion with an investigational device (ASAHI PTCA Guidewire or ASAHI Corsair Microcatheter). Clinical evaluation up to hospital discharge is conducted on all enrolled subjects. The purpose of the clinical follow-up is to determine if the subject has experienced or is experiencing any adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Procedural Time</title>
          <description>The length of the procedure (The first successful insertion of the guide catheter at an arteriotomy site is considered the start of the procedure. A procedure is considered complete once the guide catheter is removed from the arteriotomy site.)</description>
          <population>Data collected for 162 of 163 subjects</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.5" spread="68.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Contrast Volume</title>
        <description>Volume of contrast administered during procedure</description>
        <time_frame>During Procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crossing of Coronary Artery CTO</title>
            <description>This is a single arm intent to treat study. A subject is considered enrolled when the subject has given informed consent and meets all inclusion and exclusion criteria, including angiographic inclusion and exclusion criteria, which includes an attempt to cross the target lesion with an investigational device (ASAHI PTCA Guidewire or ASAHI Corsair Microcatheter). Clinical evaluation up to hospital discharge is conducted on all enrolled subjects. The purpose of the clinical follow-up is to determine if the subject has experienced or is experiencing any adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Contrast Volume</title>
          <description>Volume of contrast administered during procedure</description>
          <units>milliliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287.3" spread="141.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Absorbed Radiation Dose in mGy</title>
        <description>Absorbed radiation dose in mGy during procedure</description>
        <time_frame>During Procedure</time_frame>
        <population>Data recorded for 161 of 163 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Crossing of Coronary Artery CTO</title>
            <description>This is a single arm intent to treat study. A subject is considered enrolled when the subject has given informed consent and meets all inclusion and exclusion criteria, including angiographic inclusion and exclusion criteria, which includes an attempt to cross the target lesion with an investigational device (ASAHI PTCA Guidewire or ASAHI Corsair Microcatheter). Clinical evaluation up to hospital discharge is conducted on all enrolled subjects. The purpose of the clinical follow-up is to determine if the subject has experienced or is experiencing any adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absorbed Radiation Dose in mGy</title>
          <description>Absorbed radiation dose in mGy during procedure</description>
          <population>Data recorded for 161 of 163 subjects</population>
          <units>milligray (mGy)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2612.7" spread="1881.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedural Success (Evaluated According to Crossing Technique)</title>
        <description>The percentage of subjects with procedure success according to crossing technique</description>
        <time_frame>Through hospital discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antegrade Only</title>
            <description>Subjects where only an antegrade crossing techinique was used.</description>
          </group>
          <group group_id="O2">
            <title>Retrograde Only</title>
            <description>Subjects where only a retrograde crossing technique was used</description>
          </group>
          <group group_id="O3">
            <title>Antegrade and Retrograde</title>
            <description>Subjects were both antegrade and retrograde techniques were used</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Success (Evaluated According to Crossing Technique)</title>
          <description>The percentage of subjects with procedure success according to crossing technique</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Crossing of Coronary Artery CTO</title>
          <description>This is a single arm intent to treat study. A subject is considered enrolled when the subject has given informed consent and meets all inclusion and exclusion criteria, including angiographic inclusion and exclusion criteria, which includes an attempt to cross the target lesion with an investigational device (ASAHI PTCA Guidewire or ASAHI Corsair Microcatheter). Clinical evaluation up to hospital discharge is conducted on all enrolled subjects. The purpose of the clinical follow-up is to determine if the subject has experienced or is experiencing any adverse events.
Crossing of Coronary Artery CTO: Standard angiographic procedures will be followed for this study. The primary objective of this trial is to evaluate confirmation of placement of any guidewire beyond the chronic total occlusion (CTO) in the true vessel lumen in patients in which at least one Asahi series of guidewires and/or Corsair microcatheter were used.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Coronary artery perforation</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pulseless electrical activity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Vascular stent thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Vascular procedure complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI may publish the results of its data 1 year after completion of the Study. Sponsor can review results prior to public release and embargo communications regarding results for a period â‰¤60 days from the time submitted to the sponsor for review. Sponsor may request in writing (a) deletion of any Confidential Information, (b) reasonable changes requested by Sponsor, or (c) delay of proposed submission for another period â‰¤90 days in order to protect the potential patentability of any technology.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Ricker</name_or_title>
      <organization>Asahi Intecc USA, Inc.</organization>
      <phone>408.429.3749</phone>
      <email>robertr@asahi-intecc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

